María José Mela Osorio

María José Mela Osorio

Auto-generated profile, based on publicly available information

María José Mela Osorio

Fundaleu, Buenos Aires, Argentina

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 May 2020 in Cancers
Verified
Journal Article
Open access
PDF file
MSMarta Sobas
Marta Sobas
MTMaria Carme Talarn-Forcadell
Maria Carme Talarn-Forcadell
DMDavid Martínez-Cuadrón
David Martínez-Cuadrón
LELourdes Escoda
Lourdes Escoda
MPMARIA JOSE GARCIA PEREZ
MARIA JOSE GARCIA PEREZ
PMPau Montesinos
Pau Montesinos
It has been suggested that 1–2% of acute promyelocytic leukemia (APL) patients present variant rearrangements of retinoic acid receptor alpha (RARα) fusion gene, with the promyelocytic leukaemia zinc finger (PLZF)/RARα being the most frequent. Resistance to all-trans-retinoic acid (ATRA) and arsenic trioxide (ATO) has been suggested in PLZF/RARα and other variant APLs. Herein, we analyze the incidence, characteristics, and outcomes of variant APLs reported to the multinational PETHEMA (Programa para el Tratamiento de Hemopatias Malignas) registry, and we perform a systematic review in order to shed light on strategies to improve management of these extremely rare diseases. Of 2895 patients with genetically confirmed APL in the PETHEMA registry, 11 had variant APL (0.4%) (9 PLZF-RARα and 2 NPM1-RARα), 9 were men, with median age of 44.6 years (3 months to 76 years), median leucocytes (WBC) 16.8 × 109/L, and frequent coagulopathy. Eight patients were treated with ATRA plus chemotherapy-based regimens, and 3 with chemotherapy-based. As compared to previous reports, complete remission and survival was slightly better in our cohort, with 73% complete remission (CR) and 73% survival despite a high relapse rate (43%). After analyzing our series and performing a comprehensive and critical review of the literature, strong recommendations on appropriate management of variant APL are not possible due to the low number and heterogeneity of patients reported so far.

29 April 2022 in JCO Global Oncology
Verified
Journal Article
Open access
MPMiguel Pavlovsky
Miguel Pavlovsky
DCDaniel de Iracema Gomes Cubero
Daniel de Iracema Gomes Cubero
GAGladys Patricia Agreda-Vásquez
Gladys Patricia Agreda-Vásquez
AEAlicia Enrico
Alicia Enrico
MMMaria J. Mela-Osorio
Maria J. Mela-Osorio
PVPamella Villanova
Pamella Villanova
PURPOSE: Real-world evidence on non-Hodgkin lymphoma (NHL) management in Latin America is currently lacking. The objective of this study was to describe treatment characteristics and outcomes of NHL in Latin America. METHODS: A total of 2,967 patients with NHL with aggressive and indolent subtypes, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle-cell lymphoma (MCL), and mucosa-associated lymphoid tissue (MALT) lymphoma, with incident or prevalent diagnosis between 2006 and 2015, were retrospectively identified using clinical charts registered in the Hemato-Oncology Latin America Observational Registry. Associations between treatment regimen and age at diagnosis with clinical outcomes within each subtype were estimated using Cox proportional hazard regression. RESULTS: Most patients with NHL received 1L chemoimmunotherapy, most commonly cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) with/without rituximab. Five-year survival rates were higher for MALT lymphoma (90.8%) and FL (87.6%) versus DLBCL (69.0%) and MCL (57.1%), with variations between countries. The median overall survival from first relapse for patients with DLBCL was 6.6 years, with lower risk of death for those diagnosed at age < 65 years (hazard ratio = 0.732; P = .0161). Patients achieved a longer median progression-free survival with 1L rituximab-CHOP (R-CHOP) versus CHOP or rituximab, cyclophosphamide, vincristine, and prednisone (RCVP) (7.7 v 3.0 or 1.8 years, respectively). Use of regimens other than R-CHOP was associated with a higher risk of death/progression for patients with DLBCL (rituximab, ifosfamide, carboplatin, and etoposide/ifosfamide, carboplatin, and etoposide) and FL (CHOP). There was no relationship between treatment prescribed and age at diagnosis with outcomes from first/second relapse in DLBCL and FL. CONCLUSION: Differences in treatment outcomes between NHL subtypes were observed, reflecting variations in NHL management and barriers to treatment access in Latin America. These data provide necessary evidence to understand NHL management in this region and highlight the need to improve treatment outcomes for these patients.

26 October 2023 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Closed access
MOMaría José Mela Osorio
María José Mela Osorio
BMBeatriz Moiraghi
Beatriz Moiraghi
MOMaría Victoria Osycka
María Victoria Osycka
MPMiguel A. Pavlovsky
Miguel A. Pavlovsky
AVAna Inés Varela
Ana Inés Varela
CPCarolina Pavlovsky
Carolina Pavlovsky

9 March 2023 in Annals of Hematology
Verified
Journal Article
Closed access
PDF file
LFLuciana C Ferrari
Luciana C Ferrari
MRMaría M Rivas
María M Rivas
ANAlicia B Navickas
Alicia B Navickas
HDHernán Dick
Hernán Dick
MOMaría J Mela Osorio
María J Mela Osorio
O(On Behalf Of The Grupo Argentino de Leucemias Agudas (Gala) And Grupo Argentino de Tratamiento de Leucemias Agudas (Gatla)
On Behalf Of The Grupo Argentino de Leucemias Agudas (Gala) And Grupo Argentino de Tratamiento de Leucemias Agudas (Gatla)

14 July 2023 in Seminars in Hematology
Verified
Journal Article
Closed access
MOMaría José Mela Osorio
María José Mela Osorio
CPCarolina Pavlovsky
Carolina Pavlovsky
MPMiguel Arturo Pavlovsky
Miguel Arturo Pavlovsky

26 July 2024 in Annals of Laboratory Medicine
Verified
Journal Article
Open access
PDF file
MLMarco Lincango
Marco Lincango
VAVerónica Andreoli
Verónica Andreoli
HRHernán García Rivello
Hernán García Rivello
ABAndrea Bender
Andrea Bender
ACAna I Catalán
Ana I Catalán
CBCarolina B. Belli
Carolina B. Belli
Marco Lincango, M.S., Verónica Andreoli, Ph.D., Hernán García Rivello, Ph.D., Andrea Bender, Biochem., Ana I Catalán, M.S., Marilina Rahhal, Biochem., Rocío Delamer, Biochem., Mariana Asinari, Biochem., Adrián Mosquera Orgueira, Ph.D., María Belén Castro, M.D., María José Mela Osorio, M.D., Alicia Navickas, M.D., Sofia Grille, Ph.D., Evangelina Agriello, Biochem., Jorge Arbelbide, M.D., Ana Lisa Basquiera, Ph.D., and Carolina B Belli, Ph.D.. Ann Lab Med -0001;0:. https://doi.org/10.3343/alm.2024.0089